Case Report: Intraocular Hemorrhage in a Primary Vitreoretinal Lymphoma Patient Treated With Zanubrutinib

Frontiers in Medicine

article

Xiao Zhang¹  Rongping Dai¹  Chan Zhao¹  Meifen Zhang¹ 

[1] Department of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences;Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

关键词: primary vitreoretinal lymphoma;    intraocular hemorrhage;    zanubrutinib;    bruton tyrosine kinase inhibitor;    intravitreal injection;   

DOI  :  10.3389/fmed.2022.833565

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Purpose To report a case of primary vitreoretinal lymphoma (PVRL) treated with oral zanubrutinib, who had bilateral intraocular hemorrhage after intravitreal injection of methotrexate (MTX). Case report A 69-year-old Chinese female presented with vision decrease in both eyes. After diagnostic vitrectomy, the patient was diagnosed as PVRL in both eyes, and was treated with intravenous rituximab, oral zanubrutinib and bilateral intravitreal MTX. There were bilateral anterior chamber and vitreous hemorrhage after the fourth intravitreal MTX combined with paracentesis. After discontinuation of zanubrutinib, vitrectomy and silicon oil tamponade were performed on the left eye, and the blood in the right eye was absorbed. Conclusion Bleeding is a major concern in the use of zanubrutinib. It is suggested that drugs be held for a few days prior to procedures and surgeries.

【 授权许可】

CC BY